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Aims To identify the effect of early revascularization on 5-year survival in patients with CAD diagnosed by coronary-
computed tomographic angiography (CCTA).
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Methods
and results
We examined 5544 stable patients with suspected CAD undergoing CCTA who were followed a median of
5.5 years in a large international registry. Patients were categorized as having low-, intermediate-, or high-risk CAD
based on CCTA findings. Two treatment groups were defined: early revascularization within 90 days of CCTA (n
= 1171) and medical therapy (n = 4373). To account for the non-randomized referral to revascularization, we de-
veloped a propensity score by logistic regression. This score was incorporated into Cox proportional hazard mod-
els to calculate the effect of revascularization on all-cause mortality. Death occurred in 363 (6.6%) patients and
was more frequent in medical therapy. In multivariable models, when compared with medical therapy, the mortality
benefit of revascularization varied significantly over time and by CAD risk (P for interaction 0.04). In high-risk
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CAD, revascularization was significantly associated with lower mortality at 1 year (hazard ratio [HR] 0.22, 95%
confidence interval [CI] 0.11–0.47) and 5 years (HR 0.31, 95% CI 0.18–0.54). For intermediate-risk CAD, revascula-
rization was associated with reduced mortality at 1 year (HR 0.45, 95% CI 0.22–0.93) but not 5 years (HR 0.63,
95% CI 0.33–1.20). For low-risk CAD, there was no survival benefit at either time point.
                                                                                                                                                                                                                   
Conclusions Early revascularization was associated with reduced 1-year mortality in intermediate- and high-risk CAD detected
by CCTA, but this association only persisted for 5-year mortality in high-risk CAD.
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Introduction
The benefit of coronary revascularization on survival in stable pa-
tients with obstructive coronary artery disease (CAD) remains a sub-
ject of active study. Older studies suggested a benefit among high-risk
CAD patients1 but this benefit has not been observed in lower risk
CAD patients or in recent large-scale clinical trials of mostly inter-
mediate risk CAD patients.2,3 Recently, the emergence of coronary-
computed tomographic angiography (CCTA) to non-invasively de-
tect CAD has raised further questions about invasive treatment of
visualized obstructive lesions. Patients undergoing CCTA for sus-
pected CAD are more likely to have downstream revascularization
procedures performed4 and prior research has observed a mortality
benefit for early revascularization following CCTA in patients with
high-risk CAD in the short-term.5 However, the long-term impact of
revascularization on CAD detected by CCTA remains unknown.
The goal of the present study was to determine the long-term impact
of coronary revascularization compared with medical therapy on all-
cause survival, and its interaction with the severity of CAD by CCTA,
from a large international, observational cohort.
Methods
Patients
This was a study of stable patients without known CAD or suspected
acute coronary syndrome undergoing CCTA from the long-term
CONFIRM registry (Coronary CT Angiography EvaluatioN For Clinical
Outcomes: An InteRnational Multicenter Registry), the methods of which
have been previously described.6 CONFIRM enrolled consecutive adults
>_18 years of age between 2005 and 2009 who underwent >_64-detector
row CCTA for suspected CAD. The long-term registry includes data on
12 086 subjects who underwent CCTA at 17 centres in 9 countries
(Austria, Canada, Germany, Israel, Italy, Portugal, South Korea,
Switzerland, and USA). Institutional review board approval was obtained
at each site, and the study complies with the Declaration of Helsinki.
This analysis excluded patients with at sites that did not collect revasculari-
zation data (n = 5139). Patients with known CAD, as defined by prior myo-
cardial infarction or prior coronary revascularization (n = 1026) or those
with missing basic demographic or CCTA data (n = 238) were excluded.
Additionally, patients with myocardial infarction prior to any revascularization
procedure within the first 7 days after the CCTA (n = 139) were excluded
from this analysis in order to minimize the misclassification of potentially un-
stable patients. The final sample included 5544 patients from 12 clinical sites.
As detailed elsewhere,5–7 prior to the scan, demographic and categor-
ical cardiac risk factor data were systematically collected for each consecu-
tive patient. Hypertension was defined as a documented history of high
blood pressure or treatment with anti-hypertensive medications. Diabetes
mellitus was defined by diagnosis of diabetes made previously by a phys-
ician and/or use of insulin or oral hypoglycemic agents. Dyslipidemia was
defined as known but untreated dyslipidemia, or current treatment with
lipid-lowering medications. A positive smoking history was defined as cur-
rent smoking or cessation of smoking within 3 months of testing. Family
history of coronary heart disease was determined by patient query, and it
was defined as a primary relative with a diagnosis early in life (i.e. mother
<65 years of age or father <55 years of age). Symptom presentation was
classified into one of three categories: typical chest pain/dyspnea, atypical
chest pain, and non-cardiac pain/asymptomatic.
CCTA performance and interpretation
Standardized protocols for image acquisition, as defined by the Society of
Cardiovascular-Computed Tomography (SCCT), were employed at all
participating sites.8 Specific details of CCTA procedures have been defined
in detail elsewhere.6 All scans were analysed by level III-equivalent cardi-
ologists or radiologists in direct accordance with SCCT guidelines. Each
site applied a standard 16-segment anatomic segmental analysis for image
interpretation. In all individuals, irrespective of image quality, every arterial
segment was scored in an intent-to-diagnose fashion. All segments were
coded for the presence and severity of coronary stenosis and were scored
as normal (0% luminal stenosis), mild-moderate (1–49%), moderate (50–
69%) or severe (>_70%). If a coronary artery segment was uninterpretable
despite multiple reformatting techniques, the un-evaluable segment was
scored similar to the most proximal segment that was evaluable. Extent of
obstructive CAD was defined by >_ 50% stenosis in 0, 1, 2, or 3 coronary
artery vessels. Left main artery disease was grouped with three-vessel ob-
structive coronary artery disease. All imaging findings were site-
adjudicated; primary imaging data were not available for review.
Coronary artery disease severity was determined by both clinical plaque
scores and the modified Duke CAD score. Plaque scores included segment
stenosis score (SSS, range 0–48) and the segment involvement score (SIS,
range 0–16) as previously described.7 As in prior work,5 CAD severity was
also assessed using the modified Duke score. The groups include: Group 0
= No CAD; Group 1 = >_1 segment with 1–49% stenosis; Group 2 = >_2
segments with 1–49% stenosis AND at >_ 1 proximal segment with any
stenosis; Group 3 = >_1 segment with 50–69% stenosis; Group 4 = >_2 seg-
ments with 50–69% stenosis OR >_ 1 segment with >_70% stenosis; Group
5 = >_3 segments with 50–69% stenosis OR >_ 2 segments with >_70% sten-
osis OR proximal LAD with >_70% stenosis; Group 6 = >_3 segments with
>_70% stenosis OR >_ 2 segments with >_70% stenosis AND proximal LAD
with >_70% stenosis); Group 7 = left main with >_50% stenosis. Based upon
these gradations and their associated prognoses, patients were categorized
into three separate groups: low-risk (Groups 0–2), intermediate-risk
(Groups 3–4), and high-risk (Groups 5–7).
Post-test outcomes
Patients were followed prospectively over the course of at least 5 years
(median 5.5 years, interquartile range 5.1–6.2 years). The primary
842 J. Schulman-Marcus et al.
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outcome measure was all-cause mortality. As in previous work,5 the pri-
mary exposure was early post-CCTA revascularization. Early revasculari-
zation was defined as having occurred in the first 90 days following
CCTA, and was selected based upon prior published studies that have
indicated that this timeframe is consistent with treatment based upon
test findings (i.e. within a general episode of care).9,10
Follow-up procedures were approved by all study centres’ institutional
review boards. All-cause mortality was adjudicated by trained study per-
sonnel or by querying of national medical databases. Myocardial infarction
was site-adjudicated through a combination of direct questioning of pa-
tients using a scripted interview as previously described.6 Late revasculari-
zation was not available as an endpoint for the present analysis.
Statistical analysis and study design
Categorical variables are presented as frequencies and percentages.
Continuous variables are presented as means ± 1 SD or medians (inter-
quartile range) when appropriate. Variables were compared with v2 statis-
tic for categorical variables and by Student’s unpaired t-test or Wilcoxon
non-parametric test where appropriate for continuous variables.
In order to examine the effects of early revascularization vs. medical
therapy alone on the primary outcome, we performed a two-step statis-
tical procedure similar to prior work.5,11 We developed a propensity
score for early revascularization, then performed multivariable Cox pro-
portional hazards regression adjusted for the propensity score. The pro-
pensity score was developed using a backward stepwise logistic
regression model that summarized predictors of referral of patients to
revascularization or medical therapy. All potential factors known to influ-
ence this referral pattern were included in the propensity score develop-
ment with significant factors (as defined by P <_0.10) retained, to define a
summary measure for likelihood of revascularization. It must be noted
that the CONFIRM long-term study sites were somewhat different than
those in the previously reported short-term study,5 and therefore the
propensity score presented here was constructed de novo.
Univariate and multivariate propensity-adjusted Cox proportional haz-
ards models were then used to determine the relationship of early revas-
cularization or medical therapy for time to death by all causes. This
approach controlled for the effect of baseline differences in the compara-
tor cohorts as well as the impact of non-randomized treatment allocation
on survival. Hazard ratios (HR) and 95% confidence intervals (95% CI)
were calculated from the Cox models for the endpoint of all-cause mor-
tality. For coherence, sensitivity analyses were performed using the final
multivariable Cox model in selected subgroups of interest as well as for
the secondary outcome of first major adverse cardiac event (MACE =
death or non-fatal acute coronary syndrome). Model over-fitting proced-
ures and interaction testing were carefully considered. A two-tailed P
value of < 0.05 for association and P < 0.10 for interaction was considered
statistically significant. Analyses were performed using SAS 9.3 (Cary,
NC) and STATA version 13 (College Station, TX).
Results
Clinical characteristics of the study
cohort
Baseline characteristics of the patient sample categorized by initial
treatment strategy are listed in Table 1. Compared with patients
undergoing medical therapy, patients undergoing early revasculariza-
tion were older, more likely to be male, and more likely to have
CAD risk factors including hypertension, hyperlipidemia, diabetes, to-
bacco use, and a family history of CAD. Patients undergoing early
revascularization were more likely to have typical angina, obstructive
CAD as defined by CCTA, and an intermediate- or high-risk Duke
score than those treated medically.
Clinical treatment and events
Among the 1171 individuals undergoing early revascularization, 1001
(85.5%) underwent percutaneous coronary intervention (PCI) and
170 (14.5%) coronary artery bypass surgery (CABG).
Revascularization was performed in 2.7% of patients with low-risk
CAD, 42.1% with intermediate risk CAD, and 62.7% with high risk
CAD (P < 0.001). During follow-up, a total of 363 deaths occurred
(6.6% of the entire population). As stratified by the initial treatment
method, death occurred in 318 (7.3%) of patients treated with med-
ical therapy and 45 (3.8%) of patients treated with early coronary
revascularization (P < 0.001).
The unadjusted relationship between CAD severity and incidence
of all-cause mortality with respect to early revascularization vs. med-
ical therapy can be observed in Figure 1. The unadjusted incidence of
death was significantly increased for medical therapy in high-risk (3.1
vs. 1.0%, P < 0.001), trended toward increased in intermediate-risk
(1.6 vs. 1.0%, P = 0.06) but not increased in low-risk CAD (1.1 vs.
1.3%, P = 0.8). The observed survival differences in the intermediate
.................................................................................................
Table 1 Demographics
Medical
therapy
(n54373)
Early
revascularization
(n51171)
P value
Age (years) ± SD 59.4 ± 12.0 63.3 ± 10.1 <0.0001
Male sex % (n) 61.1 (2672) 72.4 (848) <0.001
Cardiovascular
risk factors % (n)
Hypertension 53 (2305) 63 (733) <0.001
Hyperlipidemia 51.6 (2247) 64.3 (746) <0.001
Diabetes 14.8 (643) 25.5 (297) <0.001
Current smoker 20.3 (878) 25.7 (299) <0.001
Family history
of premature CAD
29.4 (1269) 32.6 (375) <0.001
Chest pain, % (n) <0.001
Typical 28.9 (1248) 41.8 (483)
Atypical 25.9 (1120) 23.8 (275)
Non-cardiac/
asymptomatic
45.2 (1949) 34.4 (397)
Presence of
CAD by CCTA % (n)
<0.001
Normal 41.4 (1799) 2.5 (29)
Non-obstructive CAD 36.8 (1608) 5.8 (68)
Obstructive CAD 22.1 (966) 91.7 (1074)
Duke CAD Score % (n) <0.001
Low-risk (Score 0–2) 77.9 (3407) 8.3 (97)
Intermediate-risk
(Score 3–4)
13.2 (576) 35.8 (419)
High-risk (Score 5–7) 8.9 (390) 55.9 (655)
CCTA, coronary-computed tomographic angiography.
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..and high risk groups emerged early in the study period and persisted
over the 5-year study period (Figure 2A–C).
Propensity score
The logistic regression analysis results are shown in Table 2.
Significant predictors of referral to coronary revascularization
included age, sex, hyperlipidemia, typicality of symptoms, the pre-test
probability of CAD as calculated by the method of Diamond and
Forrester,12 the presence of obstructive CAD, clinical plaque scores,
and clinical site). Interactions between sex and symptom typicality as
well as age and SSS were also significant and included in the final pro-
pensity score model (C-index 0.92, v2 = 15.2, P = 0.056).
Survival analysis
Univariate Cox proportional hazards models predicting all-cause
mortality are shown in Table 3. The final multivariable Cox regression
model included age (linear and non-linear), hypertension, diabetes,
smoking, symptom typicality, Duke CAD score, early revasculariza-
tion (vs. medical therapy), and the propensity score predicting refer-
ral to revascularization. When checking the proportional hazards
assumptions for the Cox model, a significant time effect was
observed to interact with Duke CAD score. To account for this, two
additional terms were added to the final Cox regression model; the
first was a two-way interaction between time and the Duke CAD
score, and the second was a three-way interaction between time,
Duke CAD score, and early revascularization.
Using the final multivariable model, the hazard ratios for early
revascularization for all-cause mortality were estimated at both
1 year and 5 years. When compared with medical therapy, early
revascularization was associated with lower mortality at both 1 year
and 5 years for patients with high risk CAD (Figure 3). In contrast, in
patients with intermediate risk CAD, early revascularization was
Figure 1 Incidence of all-cause mortality by treatment and Duke CAD score. The unadjusted incidence of death was significantly increased for
medical therapy in high-risk, trended toward increased in intermediate-risk, but was but not increased in low-risk CAD.
Figure 2 Kaplan–Meier survival curves by severity of CAD. The five unadjusted observed survival differences were similar in low risk (A) but
diverged early in the intermediate (B) and high risk groups (C).
844 J. Schulman-Marcus et al.
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associated with reduced mortality at 1 year but not at 5 years, while
in low-risk CAD there was no survival benefit from early revasculari-
zation at either time point. There was a significant interaction be-
tween severity of CAD and revascularization that increased over
time (P value for interaction of revascularization, Duke CAD score,
and time = 0.039).
Sensitivity analyses for coherence were performed using the final
multivariable model. Findings were similar after the exclusion of ob-
structive left main artery disease, in models stratified by revasculariza-
tion technique (PCI vs. CABG), and using the outcome of MACE.
Discussion
In this large, international observational registry of stable patients
without known CAD undergoing CCTA, we observed a mortality
benefit persisting to 5 years for early post-test coronary revasculari-
zation in patients with high-risk CAD. This includes patients with mul-
tivessel obstructive CAD, obstructive disease of the proximal left
anterior descending artery, and/or obstructive disease of the left
main coronary artery. In contrast, patients with lesser severity of
CAD undergoing early revascularization did not experience any sus-
tained change in survival over this longer time frame.
Our findings expand upon the prior literature from this registry on
the relative benefit of early post-test revascularization vs. medical
therapy for CAD detected by CCTA. In a study by Min et al. of
15 223 CONFIRM registry patients with a median follow-up of
2.1 years, patients with high risk CAD (Duke CAD score 5–8)
undergoing revascularization had reduced mortality (HR 0.38, 95%
CI 0.18–0.83) while those with lower risk CAD (Duke CAD score
0–4) did not (HR 3.24, 95% CI 0.76–13.89, P for interaction 0.03).
While the overall study population was larger in the prior study, the
long-term follow-up presented here had nearly 4 times the number
of deaths and over twice as much time available for analysis. Notably,
this longer term study demonstrates the durability of mortality bene-
fit for early revascularization among patients with high-risk CAD, and
the persistent absence of long-term benefit among those with low-
risk CAD. It is interesting that the intermediate-risk patients demon-
strated an early mortality benefit that dissipated over the long term,
although given the wide confidence interval, a smaller protective
benefit cannot be excluded among these patients.
Other recently reported CCTA studies have not had sufficient
mortality rates to detect downstream mortality differences resulting
from post-test revascularization,10,13 which may reflect lower inclu-
sion of patients with high-risk CAD. In contrast, the CONFIRM regis-
try was explicitly designed to determine the prognostic value of
CCTA findings.6 Entry was not restricted to patients with suspected
CAD alone, but rather was representative of physician referral at nu-
merous high-volume sites around the world. As such, patients at
higher risk or with known CAD were enrolled, as were lower risk pa-
tients who had a CCTA performed for other diagnostic purposes
such as a family history of CAD. Although some of these indications
are currently discouraged, most CCTAs in this study were per-
formed in the years before the creation of appropriate use criteria,
and their inclusion allow for an unbiased assessment of an ‘all comers’
population of individuals undergoing CCTA.6
Our study contributes to literature documenting the adverse
prognosis of increasing anatomic CAD (detected both invasively and
by CCTA)7,14 and the debated role of subsequent revascularization
following diagnostic imaging. Observational studies predating modern
optimal medical therapy (OMT) demonstrated a survival benefit for
predominantly surgical revascularization of high-risk CAD,1 a finding
that persists in clinical guidelines of stable ischemic heart disease.15
Conversely, on the whole contemporary randomized trials of
intermediate-to-high risk CAD2,3 have not identified an association
between revascularization and a subsequent reduction of death as
compared with OMT. Furthermore, in COURAGE, there was no sig-
nificant interaction between treatment strategy and angiographic se-
verity for mortality benefit,16 a finding reflected in our observations
of patients with low and intermediate risk CAD. However, these tri-
als had several limitations. First, inclusion was contingent on pre-trial
invasive angiography, raising concerns of negative selection bias
against patients with high-risk CAD.17 Second, percutaneous revascu-
larization was mostly performed with earlier stent generations, while
a recent meta-analysis found a mortality benefit in trials using second-
generation drug eluting stents compared with medical therapy.18
Third, patients with the highest risk CAD (i.e. left main) were
.................................................................................................
Table 2 Logistic regression results for creation of
propensity score
Variable Odds ratio
(95% CI)
P value
Age 1.03 (1.00–1.06) 0.04
Sex 1.33 (0.95–1.87) 0.10
Hyperlipidemia 1.46 (1.19–1.80) <0.001
Symptom typicality <0.001
Asymptomatic/non-cardiac
chest pain
Reference
Atypical angina 1.45 (0.97–2.15)
Typical angina 2.22 (1.30–3.77)
Diamond-Forrester probability 1.67 (0.99–2.81) 0.06
Obstructive CAD <0.001
Normal Reference
Non-obstructive 0.75 (0.41–1.37)
Obstructive 5.83 (3.12–10.89)
SIS (log-transformed) 0.29 (0.17–0.50) <0.001
SSS (log-transformed) 32.1 (11.58–88.97) <0.001
Site <0.001
A 0.29 (0.17–0.49)
B 1.02 (0.65–1.59)
C 5.16 (3.37–7.91)
D 0.27 (0.19–0.38)
E 0.07 (0.03–0.17)
F 0.89 (0.62–1.29)
G 1.72 (0.76–3.92)
H 0.58 (0.38–0.88)
I 0.48 (0.34–0.68)
J 1.25 (0.42–3.69)
Sex vs. typicality 0.77 (0.60–0.99) 0.04
Age vs. SSS 0.98 (0.96–0.99) 0.001
SIS, Segment Involvement Score; SSS, Segment Stenosis Score.
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.systematically excluded, as they are from the ongoing ISCHEMIA trial
[NCT 01471522]). Indeed, revascularization to reduce mortality in
such patients has long been recommended by guidelines based pri-
marily on the work of clinical trials predating modern OMT.15,19
In this context, it is possible that the patients in CONFIRM with high-
risk CAD who were medically treated were inherently ‘sicker’, which
may contribute to higher observed mortality despite careful statistical
adjustment. This type of potential confounding is best mitigated by a
......................................................... ..............................................................
....................................................................................................................................................................................................................
Table 3 Cox proportional hazard models for the prediction of all-cause mortality
Univariate Multivariate
HR 95% CI P value HR 95% CI P value
Age (linear) 1.07 1.06–1.08 <0.001 0.88 0.82–0.94 <0.001
Age vs. age (non-linear) 1.00 1.00–1.01 <0.001 1.002 1.001–1.002 <0.001
Male sex 0.92 0.75–1.14 0.47
Hypertension 1.73 1.39–2.16 <0.001 1.34 1.03–1.75 0.03
Hyperlipidemia 0.79 0.65–0.98 0.03
Diabetes 1.81 1.43–2.30 <0.001 1.66 1.26–2.18 <0.001
Smoking 1.36 1.08–1.72 0.01 1.80 1.37–2.36 <0.001
Family history 0.69 0.54–0.89 0.004
Symptoms
Asymptomatic/non-cardiac 1.00 ref ref 1 Ref. Ref.
Atypical angina 0.67 0.50–0.90 0.009 0.70 0.51–0.95 0.02
Typical angina 1.26 1.00–1.58 0.05 1.03 0.78–1.37 0.84
Duke CAD Score
Low-risk 1.00 ref ref 1.00 Ref. Ref.
Intermediate-risk 1.27 0.96–1.68 0.09 1.16 0.68–1.98 0.58
High-risk 1.71 1.33–2.21 <0.001 1.84 0.92–3.70 0.09
Early revascularization 0.73 0.53–0.99 0.046 0.48 0.12–1.98 0.31
Propensity score 1.69 1.10–2.57 0.015 1.005 0.37–2.75 0.99
Early revascularization vs. intermed-risk 0.86 0.18–4.03 0.84
Early revascularization vs. high-risk 0.42 0.09–1.99 0.28
Duke Score vs. time 0.96 0.88–1.05 0.38
Early revascularization vs. Duke Score vs. time 1.09 1.00–1.18 0.039
Figure 3 Adjusted hazard of all-cause mortality for early revascularization. Early revascularization was associated with significant survival benefit at
both 1 year and 5 years in high risk CAD. In intermediate CAD, there was benefit at 1 year but not at 5 years, while in low-risk CAD there was no dif-
ference at either time point.
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randomized controlled trial, and our findings draw attention to the
continued need for such a study in high-risk patients.
Recently, the presence of ischemia (detected either non-invasively
or by invasive fractional flow reserve [FFR]) has been advocated over
isolated angiographic findings to identify patients likely to benefit
from revascularization rather than medical therapy.20 Our study can-
not test this hypothesis, as the CONFIRM registry did not collect the
results of non-invasive ischemia testing or subsequently performed
FFR. However, there remains considerable uncertainty about the in-
cremental importance of ischemia beyond anatomic findings, includ-
ing both ischemia detected non-invasively21 and by invasive FFR.22
We hope that replication of our methodology in secondary analyses
of the ongoing ISCHEMIA trial or in the future with the newly avail-
able non-invasive FFR-CCTA may shed further light on this matter.
This study is not without limitations. First, although the patient co-
horts represent a diversity of sites and countries, all results are subject
to limitations of observational data including the presence of unob-
served confounders and selection bias. However, we performed careful
statistical modelling to account for patterns of referral to coronary
revascularization vs. medical therapy within a clinically important 90-day
post-test window, as has been previously reported.5,11 Second, baseline
characteristics, including CAD risk factors, were based on patient re-
porting and were considered binary variables in accordance to prior
randomized and observational studies, rather than as continuous ones.
Thus, the duration of CAD risk factor presence and the severity of the
risk remain unknown. Likewise, the symptom severity, previous medical
therapy and prior non-invasive or invasive testing results were un-
known, and therefore the appropriateness of post-test revascularization
cannot be ascertained. Third, inclusion in this international observational
registry did not mandate the provision of post-test optimal medical
therapy. As such, medical regimens, compliance, and lifestyle changes
post-test are unknown but rather represent the ‘real world’ nature of
treatment in a large international cohort. Prior studies have found an
amplification of secondary preventive measures after cardiac CT dem-
onstrating CAD,13,23 but to what extent this was achieved in the pre-
sent study remains unknown. Finally, we examined all-cause mortality as
a primary endpoint, given its unparalleled clinical importance and free-
dom from ascertainment bias. Findings were coherent in a sensitivity
analysis using an outcome of MACE consisting of all-cause mortality and
acute coronary syndrome. Other outcomes (e.g. cause-specific mortal-
ity, stroke) were not uniformly available and deserve future study. In
spite of these limitations, this study is the largest consecutive cohort of
patients undergoing CCTA with long-term outcomes data available.
Conclusion
In this large international long-term registry of patients without
known CAD undergoing CCTA, early revascularization is associated
with reduced mortality at 5 years in patients with high-risk CAD. No
benefit from early revascularization was seen in patients with low-
risk CAD, while early mortality benefits in patients with
intermediate-risk CAD were not sustained at 5 years.
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